By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced results for the year ended October 31, 2024. The headline revenue and earnings releases were below expectations quarter, but management issued comments regarding future prospects that have us optimistic that the trend of decreasing revenue will soon be reversed. Management … Read more
By Thomas Kerr, CFA NASDAQ:SPGC READ THE FULL SPGC RESEARCH REPORT On January 27, 2025, Sacks Parente Golf (NASDAQ:SPGC) provided preliminary financial results for the 4th quarter of 2024 and full year 2024. Revenue is expected to be between $1.1 million – $1.3 million in the 4th quarter of 2024, an increase of 882% … Read more
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths … Read more
By M. Marin NASDAQ:EZFL Advancing strategy to be a leading on-demand mobile fueling company… EzFill Holdings (NASDAQ:EZFL) provides a mobile fuel delivery service that offers convenience to owners of commercial fleets and consumer vehicles. Its target market ranges from individual automobile owners to business fleets. The company brings refueling to the vehicles at their primary … Read more
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, … Read more